MX2019010904A - Conjugado de farmaco-polimero. - Google Patents

Conjugado de farmaco-polimero.

Info

Publication number
MX2019010904A
MX2019010904A MX2019010904A MX2019010904A MX2019010904A MX 2019010904 A MX2019010904 A MX 2019010904A MX 2019010904 A MX2019010904 A MX 2019010904A MX 2019010904 A MX2019010904 A MX 2019010904A MX 2019010904 A MX2019010904 A MX 2019010904A
Authority
MX
Mexico
Prior art keywords
group
drug
polymer conjugate
indicates
formula
Prior art date
Application number
MX2019010904A
Other languages
English (en)
Inventor
John Tait Russell
Craig Donohue Andrew
Marina D'souza Asha
Man Yee Ng Sarah
Sulistio Adrian
Lonsdale Birkett Stephen
Naylor Alan
Watling Jason
Valade David
Original Assignee
Polyactiva Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/458,546 external-priority patent/US10113033B2/en
Priority claimed from AU2017900888A external-priority patent/AU2017900888A0/en
Application filed by Polyactiva Pty Ltd filed Critical Polyactiva Pty Ltd
Publication of MX2019010904A publication Critical patent/MX2019010904A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/08—Polyhydrazides; Polytriazoles; Polyaminotriazoles; Polyoxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Un conjugado de polímero-prostaglandina que comprende: una estructura principal polimérica que comprende una pluralidad de restos de fórmula (I): (ver fórmula I) en donde: T representa un resto triazol; Q se selecciona independientemente en cada instancia y puede estar presente o ausente y cuando está presente representa un grupo de enlace; R se selecciona del grupo que consiste en hidrocarburo lineal o ramificado; D se selecciona de prostaglandinas; y L es un grupo de fórmula (II) (ver fórmula II) en donde R5 se selecciona de hidrógeno y alquilo C1 a C6; (R) indica el extremo del grupo enlazado al grupo R; y (D) indica el extremo del grupo unido al grupo D.
MX2019010904A 2017-03-14 2018-03-14 Conjugado de farmaco-polimero. MX2019010904A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/458,546 US10113033B2 (en) 2013-03-08 2017-03-14 Polymer conjugate for delivery of a bioactive agent
AU2017900888A AU2017900888A0 (en) 2017-03-14 Biodegradable drug-polymer conjugate
PCT/AU2018/050233 WO2018165710A1 (en) 2017-03-14 2018-03-14 Drug-polymer conjugate

Publications (1)

Publication Number Publication Date
MX2019010904A true MX2019010904A (es) 2019-12-09

Family

ID=63521659

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010837A MX2019010837A (es) 2017-03-14 2018-03-14 Conjugado biodegradable de farmaco-polimero.
MX2019010904A MX2019010904A (es) 2017-03-14 2018-03-14 Conjugado de farmaco-polimero.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019010837A MX2019010837A (es) 2017-03-14 2018-03-14 Conjugado biodegradable de farmaco-polimero.

Country Status (15)

Country Link
US (1) US11787906B2 (es)
EP (2) EP3595728A4 (es)
JP (2) JP7355649B2 (es)
KR (2) KR102642432B1 (es)
CN (2) CN110461336A (es)
AU (2) AU2018233159B2 (es)
BR (1) BR112019018914A2 (es)
CA (2) CA3054084A1 (es)
CL (1) CL2019002600A1 (es)
IL (2) IL269323B (es)
MX (2) MX2019010837A (es)
NZ (2) NZ757356A (es)
SG (2) SG11201907956UA (es)
WO (2) WO2018165710A1 (es)
ZA (2) ZA201905589B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
CA3154867A1 (en) * 2019-09-19 2021-03-25 Polyactiva Pty Ltd Biodegradable drug-polymer conjugate
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
WO2024084056A1 (en) * 2022-10-21 2024-04-25 Etherna Immunotherapies Nv Ionizable lipids

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044797B (it) 1974-10-15 1980-04-21 Ferruti Paolo Alti polimeri contenenti radicali prostaglandinici processo per la loro preparazione e loro impiego
JPH03220201A (ja) 1988-11-18 1991-09-27 Eisai Co Ltd プロスタグランジン類と多糖類の結合体
JP4419368B2 (ja) 2002-07-25 2010-02-24 小野薬品工業株式会社 プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
CN102245214B (zh) 2008-10-10 2014-10-29 波利艾克蒂瓦有限公司 生物可降解聚合物-生物活性部分缀合物
US8535655B2 (en) * 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
EP2340271B1 (en) 2008-10-10 2018-12-05 PolyActiva Pty Ltd. Polymer-bioactive agent conjugates
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
EP2437789A1 (en) 2009-06-01 2012-04-11 Ablitech, Inc. Biomolecule-polymer conjugates and methods of making same
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012075117A2 (en) 2010-12-01 2012-06-07 Ablitech, Inc. Small molecule-polymer conjugates and methods of making same
CN103813809A (zh) * 2011-04-12 2014-05-21 波利艾克蒂瓦有限公司 聚合物缀合的前列腺素类似物
JP2013035802A (ja) 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
MY190370A (en) * 2012-06-26 2022-04-18 Polyactiva Pty Ltd Polymer-nsaid conjugate
US10113033B2 (en) * 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
CA2902372C (en) * 2013-03-08 2021-06-15 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
US11207417B2 (en) 2017-03-14 2021-12-28 Polyactiva Pty Ltd Drug-polymer conjugate

Also Published As

Publication number Publication date
JP7355649B2 (ja) 2023-10-03
IL269321B (en) 2022-07-01
CN110662561A (zh) 2020-01-07
KR102642433B1 (ko) 2024-02-28
AU2018233159B2 (en) 2024-05-02
ZA201906133B (en) 2021-04-28
US20200123322A1 (en) 2020-04-23
EP3595728A4 (en) 2021-05-05
MX2019010837A (es) 2019-12-19
JP7204661B2 (ja) 2023-01-16
WO2018165710A1 (en) 2018-09-20
NZ757356A (en) 2022-10-28
AU2018233158B2 (en) 2024-04-11
SG11201907956UA (en) 2019-09-27
EP3595670A4 (en) 2021-05-12
CN110461336A (zh) 2019-11-15
BR112019018914A2 (pt) 2020-06-30
KR102642432B1 (ko) 2024-02-28
SG11201907931WA (en) 2019-09-27
JP2020510690A (ja) 2020-04-09
AU2018233159A1 (en) 2019-09-12
IL269323A (en) 2019-11-28
EP3595670A1 (en) 2020-01-22
IL269321A (en) 2019-11-28
WO2018165711A1 (en) 2018-09-20
AU2018233158A1 (en) 2019-09-12
EP3595728A1 (en) 2020-01-22
CL2019002600A1 (es) 2020-04-03
KR20190123776A (ko) 2019-11-01
NZ756626A (en) 2022-10-28
JP2020510692A (ja) 2020-04-09
IL269323B (en) 2022-07-01
KR20190124243A (ko) 2019-11-04
ZA201905589B (en) 2020-07-29
CA3054084A1 (en) 2018-09-20
CA3054328A1 (en) 2018-09-20
US11787906B2 (en) 2023-10-17

Similar Documents

Publication Publication Date Title
MX2019010904A (es) Conjugado de farmaco-polimero.
MX2008002129A (es) Polimeros solubles en aceite.
WO2008081631A1 (ja) 重合性化合物及び重合性組成物
MX2021013299A (es) Derivados de acido itaconico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable.
MY183161A (en) Anti-fouling compositions with a fluorinated oxyalkylene-containing polymer or oligomer
MX2020001734A (es) Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7).
HK1126779A1 (en) Hydrolysis resistant organomodified disiloxane surfactants
MX2016007125A (es) Una composicion de revestimiento.
GB201112382D0 (en) Curable compositions and membranes
WO2011126647A3 (en) Polymerizable isocyanurate monomers and dental compositions
PH12019550107A1 (en) Composition of mannuronic diacid
EP2444062A3 (en) Cosmetic product containing film-forming polymer
IN2014CN04648A (es)
MX2011008420A (es) Sistema de acoplamiento de enganche a presión entre piezas o miembros de acoplamiento.
MY181369A (en) Silane-containing carbinol-terminated polymers
MY150271A (en) Additive for hydraulic binder
MY161243A (en) Fluorinated aminotriazole derivatives
MY157838A (en) Metalworking fluid
MY182548A (en) Biodegradable super-spreading, organomodified trisiloxane
RS54146B1 (en) CIKLOPENTILAKRILAMIDA DERIVATIVES
WO2011061452A3 (fr) Précurseurs biscarbonates, leur procédé de préparation et leurs utilisations
MX2022000402A (es) Composicion desinfectante.
MX2009013495A (es) 3-ciclopropil-4-(3-tiobenzoil)pirazoles y su utilizacion como herbicidas.
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
MX2019006861A (es) Composicion basada en compuestos de tiosulfinato y/o tiosulfonato para su uso en la prevencion de infecciones bacterianas en animales acuaticos.